Relapsed multiple myeloma: who benefits from salvage autografts?
about
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomibOutcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation.Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation.Second autologous transplant as salvage therapy in multiple myeloma.Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
P2860
Relapsed multiple myeloma: who benefits from salvage autografts?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Relapsed multiple myeloma: who benefits from salvage autografts?
@en
type
label
Relapsed multiple myeloma: who benefits from salvage autografts?
@en
prefLabel
Relapsed multiple myeloma: who benefits from salvage autografts?
@en
P2093
P2860
P1476
Relapsed multiple myeloma: who benefits from salvage autografts?
@en
P2093
P2860
P304
P356
10.1111/J.1445-5994.2012.02867.X
P577
2013-02-01T00:00:00Z